Von 20 Cent auf 5 Euro = 2500% - 500 Beiträge pro Seite

[fohrenburg]

NWBT - Biotechperle beginnt zu steigen !!



..Chartmässig genial ""

MACD - Ausbruch
Stochastik unter 50%
RSI - am steigen

[fohrenburg]

Momentan 4 mio MK bei FDA - Zulassung 120 mio und eine Kooperation mit einer Pharmafirma ,das ist gewiss.

[fohrenburg]

Noch haben wir 2 Stunden denn Amis vorraus ,kann aber beim besten nicht sagen wo die heute eröffnen.

Könnte wirklich ein super Tag werden heute - 50 % und mehr könnten heute schon gehen.

[fohrenburg]

Rechne heute mit Riesen Ausbruch und Mega starkes Volumen.

[fohrenburg]

In Ragingbull spricht man auch schon von Kursen über 3 Dollar ""

[fohrenburg]

Die Zukunft beginnt heute
NWBT - es sieht verdammt gut aus :

Northwest Biotherapeutics, Inc. Receives Patent Coverage for Antibodies to Primary and Metastatic Cancer Protein

BOTHELL, Wash., March 21 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBT.OB) today announced that it has been issued a patent for antibodies to a protein that plays an important role in human cancer, both in primary tumors and in metastasis.

The protein, known as CXCR4, is a chemokine receptor, which is over expressed in more than 65% of human cancers, including breast, ovarian, lung, colon, prostate, kidney, melanoma, brain, esophageal, pancreatic, and many forms of leukemia, and childhood cancers such as acute lymphocytic leukemia and neuroblastoma. The patent issued is United States patent No. 6,863,887, " Therapeutic and Diagnostic Applications Based on the Role of the CXCR4 Gene in Tumorigenesis." The CXCR4 protein is unique in that it plays an important role in three fundamental aspects of cancer: cancer cell proliferation, invasion and migration, resulting in the seeding of metastatic cells at distant sites such as bone, lung and brain. It is rare for a cancer-related protein to play an important role in all three functional aspects of cancer cells, across many types of cancers. As such, CXCR4 offers an exceptional therapeutic opportunity to prevent proliferation of primary tumors, as well as to prevent metastases.

The patent issued to Northwest Biotherapeutics provides broad coverage for the use of antibodies in preventing and inhibiting the proliferation of cells that over express CXCR4, and for the killing of such cells. Additional issued claims cover the use of antibodies to CXCR4 that are conjugated with a radioactive substance, toxin or drug.

" We are particularly pleased with the CXCR4 patent which came from our gene discovery program, and which will significantly add to our product candidate pipeline," stated Alton Boynton, Ph.D., President, Chief Operating Officer, and co-founder of Northwest Biotherapeutics. " Our preclinical work clearly demonstrates an important role for CXCR4 and its ligand, CXCL12, in tumor cell proliferation, cell migration/invasion and metastasis; three critical functions of cancer cells. The central role of CXCR4 in all three functional aspects of cancer cells, provides multiple therapeutic possibilities, and certainly makes CXCR4 a premier target for novel treatments."

The pre-clinical work by Northwest Biotherapeutics is consistent with the extensive research by others, demonstrating that monoclonal antibodies to CXCR4 can prevent cancer cell proliferation, migration, and establishment of distant metastatic sites using several animal models, including those for breast cancer. Researchers have found that tumors often outgrow their blood supply, and thereby create hypoxic or low-oxygen conditions. The hypoxia results in the expression of CXCR4 which promotes the survival of tumor cells in the hypoxic environment by enabling the cancer cells to proliferate, and migrate away from areas of low oxygen, thus seeding distant metastatic sites in other organs. A positive correlation has been shown to exist in human cancer between CXCR4 expression and establishment of metastatic disease for example in, breast cancer, kidney cancer and acute childhood lymphocytic leukemia.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on discovering, developing and commercializing immunotherapy products that safely generate and enhance immune system responses to effectively treat cancer. Three technologies form the basis of our product candidates: a dendritic cell-based immunotherapy platform applicable to multiple cancers and currently cleared by the FDA for a Phase III clinical trial in non-metastatic hormone independent prostate cancer, and a Phase II clinical trial for Glioblastoma multiforme; a therapeutic monoclonal antibody product candidate, CXCR4, applicable to multiple cancer types; and an antibody-based imaging agent for metastatic prostate cancer.

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as " expects," " believes," " intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company`s ability to raise additional capital, risks related to the Company`s ability to successfully clear the FDA for Phase I clinical trials for CXCR4 in cancer patients, the clinical trial process including the ability to enroll patients in the planned Phase III trial of DCVAX(R)-Prostate, and Phase II DCVax-Brain clinical trial, and the ability to complete these trials on a timely basis, and whether these clinical trials will demonstrate safety and efficacy, and, the timely performance of third parties. Additional information on these and other factors, which could affect the Company`s results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company`s SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

SOURCE Northwest Biotherapeutics
-0- 03/21/2005
/CONTACT: Lorie Calvo of Northwest Biotherapeutics, [phone], or
[e-mail]/
/Web site: http://www.nwbio.com /
(NWBT)

CO: Northwest Biotherapeutics
ST: Washington
IN: BIO MTC HEA OTC
SU:

SF-JP
-- SFM097 --
2735 03/21/200508:00 ESThttp://www.prnewswire.com